Single Dose Administration of L-Carnitine Improves Antioxidant Activities in Healthy Subjects

L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine con...

Full description

Saved in:
Bibliographic Details
Published inThe Tohoku Journal of Experimental Medicine Vol. 224; no. 3; pp. 209 - 213
Main Authors Qu, Hai-jun, Han, Zhi-wu, Li, Ping, Wang, Le-xin, Wang, Chun-bo, Cao, Yu
Format Journal Article
LanguageEnglish
Published Japan Tohoku University Medical Press 2011
Subjects
Online AccessGet full text
ISSN0040-8727
1349-3329
1349-3329
DOI10.1620/tjem.224.209

Cover

Abstract L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 μmol/L. After single oral administration, the maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) were 84.7 ± 25.2 μmol/L and 2,676.4 ± 708.3 μmol/L·h, respectively. The half-life and the time required to reach the Cmax was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.
AbstractList L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 μmol/L. After single oral administration, the maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) were 84.7 ± 25.2 μmol/L and 2,676.4 ± 708.3 μmol/L·h, respectively. The half-life and the time required to reach the Cmax was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.
L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.
L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.
Author Wang, Chun-bo
Cao, Yu
Qu, Hai-jun
Li, Ping
Han, Zhi-wu
Wang, Le-xin
Author_xml – sequence: 1
  fullname: Qu, Hai-jun
  organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University
– sequence: 1
  fullname: Han, Zhi-wu
  organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University
– sequence: 1
  fullname: Li, Ping
  organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University
– sequence: 1
  fullname: Wang, Le-xin
  organization: School of Biomedical Sciences, Charles Sturt University
– sequence: 1
  fullname: Wang, Chun-bo
  organization: Department of Pharmacology, Medical College, Qingdao University
– sequence: 1
  fullname: Cao, Yu
  organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21701126$$D View this record in MEDLINE/PubMed
BookMark eNp1kE1PGzEQhq0KVALtrWfkWy_d4I_d9e4xTaFEisQBOFaW7R0njna9YDuo_PuaJgEJicuMNO8zo9Fzio786AGhb5RMac3IRdrAMGWsnDLSfkITysu24Jy1R2hCSEmKRjBxgk5j3BDCSyLqz-iEUUEoZfUE_bl1ftUD_jVGwLNucN7FFFRyo8ejxctiroJ3yXnAi-EhjE8Q8czn-K_rlE94ZpJ7ynkeO4-vQfVp_Yxvt3oDJsUv6NiqPsLXfT9D91eXd_PrYnnzezGfLQtTiSYVlYWOQdXxzlZU284oauuaV6JmWtu21Ex3TdOWhIrWWKoZ1LbSQpdtSSujBD9D33d384ePW4hJDi4a6HvlYdxG2QguSE0IzeT5ntzqATr5ENygwrM8GMkA2wEmjDEGsNK49N9H1uJ6SYl80S5ftMusXWbteenHu6XD3Q_wnzt8E5NawSusQnKmhzeYHyppX0OzVkGC5_8AATqdPg
CitedBy_id crossref_primary_10_1080_10408398_2023_2178379
crossref_primary_10_1111_1750_3841_12553
crossref_primary_10_2174_1574888X17666220511141123
crossref_primary_10_1089_aivt_2023_0012
crossref_primary_10_3389_fvets_2022_860771
crossref_primary_10_1590_S1984_82502013000100020
crossref_primary_10_1016_j_pestbp_2025_106301
crossref_primary_10_3390_ijms21239168
crossref_primary_10_3390_nu10030349
crossref_primary_10_3390_nu13103432
crossref_primary_10_3390_jpm13020298
crossref_primary_10_1002_ptr_6568
crossref_primary_10_1080_21655979_2020_1863618
crossref_primary_10_1038_ejcn_2017_131
crossref_primary_10_1111_bcpt_12112
crossref_primary_10_1007_s11011_025_01545_6
crossref_primary_10_1007_s11259_016_9670_9
crossref_primary_10_1016_j_foodres_2016_08_007
crossref_primary_10_1139_apnm_2014_0163
crossref_primary_10_1208_s12249_020_01852_4
crossref_primary_10_1016_j_eujim_2020_101243
crossref_primary_10_1097_MBC_0000000000000760
crossref_primary_10_1016_j_nutres_2015_06_003
crossref_primary_10_1007_s13205_023_03714_9
crossref_primary_10_1089_bio_2023_0031
crossref_primary_10_1186_1475_2891_13_79
crossref_primary_10_1021_acsinfecdis_1c00162
crossref_primary_10_1016_j_heliyon_2024_e25057
crossref_primary_10_1016_j_tice_2024_102558
crossref_primary_10_1016_j_scispo_2016_02_005
crossref_primary_10_3390_nu15112587
crossref_primary_10_1007_s13277_013_1477_5
crossref_primary_10_1186_s41100_017_0135_6
crossref_primary_10_1519_JSC_0b013e318234ebcb
crossref_primary_10_1016_j_ctim_2018_03_003
crossref_primary_10_1080_21678421_2020_1726565
crossref_primary_10_3390_antiox9121310
crossref_primary_10_1042_BSR20191601
crossref_primary_10_1002_jpn3_12351
Cites_doi 10.1016/S0378-4347(96)00219-8
10.1177/0091270006292851
10.1016/j.transproceed.2007.03.112
10.1016/j.jss.2005.12.017
10.7326/0003-4819-107-4-526
10.1042/0264-6021:3610417
10.1016/0026-0495(91)90033-S
10.1016/S0378-4347(97)00376-9
10.1002/jps.2600840520
10.1016/j.lfs.2005.05.103
10.1136/bjsm.2007.039792
10.2165/00002512-199303010-00006
10.1152/ajpcell.00333.2003
10.1016/j.cca.2006.11.008
10.3109/10408369209114601
10.1007/BF02993974
10.1093/ndt/gfi257
ContentType Journal Article
Copyright 2011 Tohoku University Medical Press
Copyright_xml – notice: 2011 Tohoku University Medical Press
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1620/tjem.224.209
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-3329
EndPage 213
ExternalDocumentID 21701126
10_1620_tjem_224_209
article_tjem_224_3_224_3_209_article_char_en
Genre Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
123
29Q
2WC
36B
3O-
53G
5RE
7.U
ABCQX
ACGFO
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DU5
E3Z
EBD
EMB
EMOBN
F5P
GX1
JSF
JSH
KQ8
L7B
MK0
OK1
OVT
P2P
RJT
RNS
RZJ
SV3
TKC
TR2
W2D
WH7
X7J
X7M
XSB
ZGI
ZXP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c578t-5fed2e5d3df51bfdca1f6635762bbf94b2bd88940179cf1b2e6f5b7b49415ca73
ISSN 0040-8727
1349-3329
IngestDate Fri Jul 11 04:17:53 EDT 2025
Mon Jul 21 05:59:36 EDT 2025
Tue Jul 01 01:28:51 EDT 2025
Thu Apr 24 22:58:58 EDT 2025
Wed Sep 03 06:12:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c578t-5fed2e5d3df51bfdca1f6635762bbf94b2bd88940179cf1b2e6f5b7b49415ca73
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/tjem/224/3/224_3_209/_article/-char/en
PMID 21701126
PQID 873706001
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_873706001
pubmed_primary_21701126
crossref_citationtrail_10_1620_tjem_224_209
crossref_primary_10_1620_tjem_224_209
jstage_primary_article_tjem_224_3_224_3_209_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-00-00
PublicationDateYYYYMMDD 2011-01-01
PublicationDate_xml – year: 2011
  text: 2011-00-00
PublicationDecade 2010
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle The Tohoku Journal of Experimental Medicine
PublicationTitleAlternate Tohoku J. Exp. Med.
PublicationYear 2011
Publisher Tohoku University Medical Press
Publisher_xml – name: Tohoku University Medical Press
References Cross, C.E., Halliwell, B., Borish, E.T., Pryor, W.A., Ames, B.N., Saul, R.L., McCord, J.M. & Harman, D. (1987) Oxygen radicals and human disease. Ann. Intern. Med., 107, 526-545.
Longo, A., Bruno, G., Curti, S., Mancinelli, A. & Miotto, G. (1996) Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracen. J. Chromatogr. B Biomed. Appl., 686, 129-139.
Van Kempen, T.A. & Odle, J. (1992) Quantification of carnitine esters by high-performance liquid chromatography: effect of feeding medium-chain triglycerides on the plasma carnitine ester profile. J. Chromatogr., 584, 157-165.
Vaz, F.M. & Wanders, R.J. (2002) Carnitine biosynthesis in mammals. Biochem. J., 361, 417-429.
Cao, Q.R., Ren, S., Park, M.J., Choi, Y.J. & Lee, B.J. (2007) Determination of highly soluble L-Carnitine in biological samples by reverse phase high performance liquid chromatography with fluorescent derivatization. Arch. Pharm. Res., 30, 1041-1046.
Sahajwalla, C.G., Helton, E.D., Purich, E.D., Hoppel, C.L. & Cabana, B.E. (1995) Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330 mg tablet versus 1 g chewable tablet versus enteral solution in healthy adult male volunteers. J. Pharm. Sci., 84, 627-633.
Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G. & Guarnieri, G. (2008) Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol. Dial. Transplant., 23, 991-997.
Lahjouji, K., Elimrani, I., Lafond, J., Leduc, L., Qureshi, I.A. & Mitchell, G.A. (2004) L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am. J. Physiol. Cell Physiol., 287, C263-C269.
Marzo, A. & Curti, S. (1997) L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J. Chromatogr. B Biomed. Sci. Appl., 702, 1-20.
Minker, P.E. & Hoppel, C.L. (1993) Quantification of carnitine and specific acylcarnitines by high-performance liquid chromatography: application to normal human urine and urine from patients with methylmalonic aciduria, isovaleric acidemia or medium-chain acyl-CoA dehydrogenase deficiency. J. Chromatogr., 613, 203-221.
Tsakiris, T., Angelogianni, P., Tesseromatis, C., Tsakiris, S. & Schulpis, K.H. (2008) Effect of L-carnitine administration on the modulated rat brain protein concentration, acetylcholinesterase, Na+K+-ATPase and Mg2+-ATPase activities induced by forced swimming. Br. J. Sports Med., 42, 367-372.
Rebouche, C.J. (1991) Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism, 40, 1305-1310.
Vernez, L., Dickenmann, M., Steiger, J., Wenk, M. & Krähenbühl, S. (2006) Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol. Dial. Transplant., 21, 450-458.
Harman, D. (1993) Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging, 3, 60-80.
Irshad, M. & Chaudhuri, P.S. (2002) Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol., 40, 1233-1239.
Akin, M., Kurukahvecioglu, O., Gulbahar, O., Isikgonul, I., Taneri, F., Tezel, E. & Onuk, E. (2007) Comparison of the effects of sodium nitroprusside and L-carnitine in experimental ischemia-reperfusion injury in rats. Transplant. Proc., 9, 2997-3001.
Li, K., Li, W. & Huang, Y. (2007) Determination of free L-carnitine in human seminal plasma by high performance liquid chromatography with pre-column ultraviolet derivatization and its clinical application in male infertility. Clin. Chim. Acta, 378, 159-163.
Onem, G., Aral, E., Enli, Y., Oguz, E.O., Coskun, E., Aybek, H., Ozcan, A.V., Sacar, M., Bir, L.S., Baltalarli, A. & Baycu, C. (2006) Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. J. Surg. Res., 131, 124-130.
Angelini, C., Vergani, L. & Martinuzzi, A. (1992) Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of β-oxidation. Crit. Rev. Clin. Lab. Sci., 29, 217-242.
Gulcin, I. (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci., 78, 803-811.
Takeyama, N., Matsuo, N., Takagi, D. & Tanaka, T. (1989) Determination of overt carnitine palmitoyltransferase by reversed-phase high-performance liquid chromatography. J. Chromatogr., 491, 69-76.
Bain, M.A., Milne, R.W. & Evans, A.M. (2006) Disposition and metabolite kinetics of oral L-carnitine in humans. J. Clin. Pharmacol., 46, 1163-1170.
11
22
12
13
15
16
17
19
(18) 1989; 491
1
2
3
(20) 1992; 584
4
5
6
7
8
9
(14) 1993; 613
10
21
References_xml – reference: Minker, P.E. & Hoppel, C.L. (1993) Quantification of carnitine and specific acylcarnitines by high-performance liquid chromatography: application to normal human urine and urine from patients with methylmalonic aciduria, isovaleric acidemia or medium-chain acyl-CoA dehydrogenase deficiency. J. Chromatogr., 613, 203-221.
– reference: Onem, G., Aral, E., Enli, Y., Oguz, E.O., Coskun, E., Aybek, H., Ozcan, A.V., Sacar, M., Bir, L.S., Baltalarli, A. & Baycu, C. (2006) Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. J. Surg. Res., 131, 124-130.
– reference: Akin, M., Kurukahvecioglu, O., Gulbahar, O., Isikgonul, I., Taneri, F., Tezel, E. & Onuk, E. (2007) Comparison of the effects of sodium nitroprusside and L-carnitine in experimental ischemia-reperfusion injury in rats. Transplant. Proc., 9, 2997-3001.
– reference: Angelini, C., Vergani, L. & Martinuzzi, A. (1992) Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of β-oxidation. Crit. Rev. Clin. Lab. Sci., 29, 217-242.
– reference: Sahajwalla, C.G., Helton, E.D., Purich, E.D., Hoppel, C.L. & Cabana, B.E. (1995) Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330 mg tablet versus 1 g chewable tablet versus enteral solution in healthy adult male volunteers. J. Pharm. Sci., 84, 627-633.
– reference: Lahjouji, K., Elimrani, I., Lafond, J., Leduc, L., Qureshi, I.A. & Mitchell, G.A. (2004) L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am. J. Physiol. Cell Physiol., 287, C263-C269.
– reference: Longo, A., Bruno, G., Curti, S., Mancinelli, A. & Miotto, G. (1996) Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracen. J. Chromatogr. B Biomed. Appl., 686, 129-139.
– reference: Bain, M.A., Milne, R.W. & Evans, A.M. (2006) Disposition and metabolite kinetics of oral L-carnitine in humans. J. Clin. Pharmacol., 46, 1163-1170.
– reference: Li, K., Li, W. & Huang, Y. (2007) Determination of free L-carnitine in human seminal plasma by high performance liquid chromatography with pre-column ultraviolet derivatization and its clinical application in male infertility. Clin. Chim. Acta, 378, 159-163.
– reference: Harman, D. (1993) Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging, 3, 60-80.
– reference: Rebouche, C.J. (1991) Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism, 40, 1305-1310.
– reference: Cao, Q.R., Ren, S., Park, M.J., Choi, Y.J. & Lee, B.J. (2007) Determination of highly soluble L-Carnitine in biological samples by reverse phase high performance liquid chromatography with fluorescent derivatization. Arch. Pharm. Res., 30, 1041-1046.
– reference: Tsakiris, T., Angelogianni, P., Tesseromatis, C., Tsakiris, S. & Schulpis, K.H. (2008) Effect of L-carnitine administration on the modulated rat brain protein concentration, acetylcholinesterase, Na+K+-ATPase and Mg2+-ATPase activities induced by forced swimming. Br. J. Sports Med., 42, 367-372.
– reference: Cross, C.E., Halliwell, B., Borish, E.T., Pryor, W.A., Ames, B.N., Saul, R.L., McCord, J.M. & Harman, D. (1987) Oxygen radicals and human disease. Ann. Intern. Med., 107, 526-545.
– reference: Takeyama, N., Matsuo, N., Takagi, D. & Tanaka, T. (1989) Determination of overt carnitine palmitoyltransferase by reversed-phase high-performance liquid chromatography. J. Chromatogr., 491, 69-76.
– reference: Van Kempen, T.A. & Odle, J. (1992) Quantification of carnitine esters by high-performance liquid chromatography: effect of feeding medium-chain triglycerides on the plasma carnitine ester profile. J. Chromatogr., 584, 157-165.
– reference: Gulcin, I. (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci., 78, 803-811.
– reference: Vaz, F.M. & Wanders, R.J. (2002) Carnitine biosynthesis in mammals. Biochem. J., 361, 417-429.
– reference: Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G. & Guarnieri, G. (2008) Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol. Dial. Transplant., 23, 991-997.
– reference: Vernez, L., Dickenmann, M., Steiger, J., Wenk, M. & Krähenbühl, S. (2006) Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol. Dial. Transplant., 21, 450-458.
– reference: Irshad, M. & Chaudhuri, P.S. (2002) Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol., 40, 1233-1239.
– reference: Marzo, A. & Curti, S. (1997) L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J. Chromatogr. B Biomed. Sci. Appl., 702, 1-20.
– ident: 4
– ident: 12
  doi: 10.1016/S0378-4347(96)00219-8
– ident: 3
  doi: 10.1177/0091270006292851
– volume: 613
  start-page: 203
  issn: 0021-9673
  issue: 2
  year: 1993
  ident: 14
– volume: 584
  start-page: 157
  issn: 0021-9673
  issue: 2
  year: 1992
  ident: 20
– ident: 1
  doi: 10.1016/j.transproceed.2007.03.112
– ident: 15
  doi: 10.1016/j.jss.2005.12.017
– ident: 6
  doi: 10.7326/0003-4819-107-4-526
– ident: 21
  doi: 10.1042/0264-6021:3610417
– ident: 16
  doi: 10.1016/0026-0495(91)90033-S
– ident: 13
  doi: 10.1016/S0378-4347(97)00376-9
– ident: 17
  doi: 10.1002/jps.2600840520
– ident: 7
  doi: 10.1016/j.lfs.2005.05.103
– ident: 19
  doi: 10.1136/bjsm.2007.039792
– ident: 8
  doi: 10.2165/00002512-199303010-00006
– ident: 10
  doi: 10.1152/ajpcell.00333.2003
– ident: 11
  doi: 10.1016/j.cca.2006.11.008
– volume: 491
  start-page: 69
  issn: 0021-9673
  issue: 1
  year: 1989
  ident: 18
– ident: 9
– ident: 2
  doi: 10.3109/10408369209114601
– ident: 5
  doi: 10.1007/BF02993974
– ident: 22
  doi: 10.1093/ndt/gfi257
SSID ssj0034076
Score 2.1324708
Snippet L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine...
SourceID proquest
pubmed
crossref
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 209
SubjectTerms Administration, Oral
Antioxidants - metabolism
Carnitine - administration & dosage
Carnitine - blood
Carnitine - pharmacokinetics
Carnitine - pharmacology
catalase
Catalase - metabolism
Dose-Response Relationship, Drug
glutathione peroxidase
Glutathione Peroxidase - metabolism
Health
Humans
L-carnitine
superoxide dismutase
Superoxide Dismutase - metabolism
Time Factors
total antioxidative capacity
Title Single Dose Administration of L-Carnitine Improves Antioxidant Activities in Healthy Subjects
URI https://www.jstage.jst.go.jp/article/tjem/224/3/224_3_209/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/21701126
https://www.proquest.com/docview/873706001
Volume 224
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX The Tohoku Journal of Experimental Medicine, 2011, Vol.224(3), pp.209-213
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7KKuKLeLfemAd9WqYmM5MbPi1FXYQVwS7UBwmZzGS3dU3EJiC--Nc9Z2aSpusurEIJJZ1J2pyv3zlz5lwIeaFDnchYJswE2jAppGaFzkqWaMNVFpZFZkspHX2ID4_l-2W0nEx-j6KWulbNyl8X5pX8j1ThHMgVs2T_QbLDReEEvAf5whEkDMcryfgT6J0zA0YwVhfZqYJrXf9sjm6PFu1I5zswGywWsGp-rjQ80P2D0raOWNmYLJ-QZKkEfTObsdm6aE6br924zMROZ4DzG_TzwjpgP3dbt6pVccWKrbttDJANJPjY607r1XfMMz_taqaasUfCc6XnVxkAv7ps_5lxlCpkxoTwfg3PudwlTntwiTGDBtlIGXOXqPoXz8ccAyPbtfk2g0vNhknjctrn1NwQfIjLHpif4-wcZuccE0Cv8SSOsQXGu-UQIyRgtRv3YZf4s3zmBMx-Nb73jk1zfQ1m_Ym5fMViLZfFbXLLLznogcPPHTIx9V1y48jL7B754mBEEUZ0F0a0qegIRrSHER3BiG5hRFc19TCiPYzuk-O3bxbzQ-a7brAS2LtlUWU0N5EWuopCVemyCCs0S0FrKlVlUnGl0zSTSOVlFSpu4ipSiZIZ2IJlkYgHZK9uavOIUJEmVZAFUVBEUhquC5WIUFemSKWWSpdTst8_t7z0JemxM8pZfpGMpuTlMPq7K8VyybjXTgTDKP8H3Y4S_THIhg8xyxFIZUpoL7ccmBa3z4raNN0mTxOBpaaCcEoeOnkON-DY1SDk8eMrfsUn5Kbbm8DXU7LX_ujMMzBuW_XcAvAPc0KpvQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Single+Dose+Administration+of+L-Carnitine+Improves+Antioxidant+Activities+in+Healthy+Subjects&rft.jtitle=Tohoku+journal+of+experimental+medicine&rft.au=Cao%2C+Yu&rft.au=Qu%2C+Hai-jun&rft.au=Li%2C+Ping&rft.au=Wang%2C+Chun-bo&rft.date=2011&rft.issn=0040-8727&rft.eissn=1349-3329&rft.volume=224&rft.issue=3&rft.spage=209&rft.epage=213&rft_id=info:doi/10.1620%2Ftjem.224.209&rft.externalDBID=n%2Fa&rft.externalDocID=10_1620_tjem_224_209
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-8727&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-8727&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-8727&client=summon